As we approach 2015, we would like to take this opportunity to thank our Editors, Reviewers, Authors and Industry Supporters for their valuable contri

 
CO-NEWSLETTER-LOGO withdate
***

As we approach 2015, we would like to take this opportunity to thank our Editors, Reviewers, Authors and Industry Supporters for their valuable contribution to the journal.

2014 was an exciting year for the journal, as highlighted by:

• An increased Impact Factor of 1.643 as published in the 2013 Journal Citation Reports, Science Edition (Thomson Reuters 2014)
• Over 380 article submissions in 2014
• Increase in visitors to www.current-oncology.com - Recent stats from Google Analytics, Google’s web site traffic analysis application, have shown over a 30% increase in the number of visitors to the website over the past year
• Encouraging score and review from MEDLINE, the U.S. National Library of Medicine (NLM) premier bibliographic database

We have exciting plans for the journal in 2015 to ensure it continues to strengthen and grow, both within Canada and Internationally. Stay tuned for more information in future newsletters!

Best wishes for a happy holiday season,

logo70

Multimed Inc.
Publisher of Current Oncology
www.multi-med.com

***
CO Twitter Banner Ad
***
InPress-CON

Volume 21, Number 6 (December 2014)

The latest issue of Current Oncology is now available online. Please visit the following link to view full text articles from this issue:
http://www.current-oncology.com/index.php/oncology/issue/current/showToc

Highlights from this issue...

BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients
W.Y. Fang, L. Ye, X.F. Zhang, et al.

Health system costs for stage-specific breast cancer: a population-based approach
N. Mittmann, J.M. Porter, J. Rangrej, et al.

Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer
B.S. Sheffield, I.E. Bosdet, R.H. Ali, et al.

Aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting after moderately emetogenic radiotherapy for bone metastases: a prospective pilot study
K. Dennis, C. De Angelis, F. Jon, et al.

***
LookingAhead-CON

Upcoming in Current Oncology

The future table of contents for Current Oncology, Volume 22, Number 1 (February 2015) is now available. For the most up-to-date listing of scheduled papers, please visit the following link:
http://www.current-oncology.com/index.php/oncology/about/futureTOC


Breast Cancer Supplement – coming in early 2015!

Current Oncology is publishing a supplement dedicated to breast cancer later this year. This supplement will cover many of the issues that physicians face on a daily basis when dealing with this disease. Dr. Maureen Trudeau (Sunnybrook Health Science Centre) is the Guest Editor, and is inviting some of the most respected Canadian authorities in this cancer to tackle the myriad of important topics that will make up this supplement.

The supplement will include Cancer Care Ontario’s most recent guidelines for the adjuvant treatment of early breast cancer including a consensus, list of recommendations and reviews on adjuvant hormones, chemotherapy and trastuzumab. Reviews of treatment for metastatic disease will also be covered.

***
EditorSpotlight
Dugald Seely OICC - Photo

Dugald Seely, ND, MSc, FABNO
Editor of our Integrative Oncology Section (since April 2012)

Dugald Seely is a naturopathic doctor and researcher who is playing a leading role in helping develop the field of integrative and naturopathic oncology. As founder and executive director of the Ottawa Integrative Cancer Centre (OICC), Dr. Seely is pioneering a contemporary cancer treatment model based on scientifically grounded, evidence-informed complementary medicine. With the establishment of the first integrative cancer care and research centre in Eastern Canada, Dr. Seely and his team are providing whole-person integrative care to people living with cancer and addressing research gaps in whole-systems of cancer care. Dr. Seely completed his M.Sc. in cancer research at the University of Toronto and is a Fellow of the American Board of Naturopathic Oncology (FABNO). As a clinician scientist, Dugald has been awarded competitive grant and trainee funding from CIHR, CBCRA, the SickKids Foundation, the Lotte and John Hecht Memorial Foundation, the Ottawa Regional Cancer Foundation, and the Gateway for Cancer Research. Dr. Seely has led numerous research projects and most recently secured funding for the largest integrative naturopathic cancer care clinical trial ever conducted in North America. In addition to clinical research, Dr. Seely has conducted and supervised dozens of synthesis reviews and meta-analyses with the goal of building on the growing body the evidence that supports integrative oncology.

Outside the clinical and leadership roles at the Ottawa Integrative Cancer Centre, Dr. Seely serves as the director of research & clinical epidemiology at the Canadian College of Naturopathic Medicine and is an affiliate investigator for the Ottawa Hospital Research Institute. Dr. Seely is also a section editor for Integrative Oncology in the Current Oncology Journal and a board member of the Oncology Association of Naturopathic Physicians (OncANP). Past board member for the Society of Integrative Oncology (SIO), Dr. Seely was also appointed to Health Canada’s Expert Advisory Panel for the Vigilance of Health Products for which he served three years. Dr. Seely has published more than 50 Medline indexed peer-reviewed publications. Dugald believes strongly in the ability of evidence-based medicine to effect positive change in the health-care system and is actively building on this base. As an educator, researcher, clinician, and frequent speaker at conferences around the world, Dugald is seeking to shift the debate towards a more whole-person cancer care model that is espoused by integrative oncology.

***
HaveYouHeard-CON

Update to Current Oncology’s Author Guidelines

We have recently made updates to our author guidelines to match the most recent guidelines released by the International Committee of Medical Journal Editors (ICMJE). Please click here to review our most up to date journal policies and guidelines. Important changes include:

Manuscript Submission Form - For all new submissions to the journal we require that the corresponding author upload a form with their submission, which acknowledges their understanding and adherence to our policies
Criteria for Authorship – A fourth criteria for authorship has been added, which states authors must agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Reporting Guidelines - Reporting guidelines raise reporting standards, allow for better validation of results during peer review and enable readers to more readily replicate the studies described. We now ask authors to follow the various reporting guidelines as outlined in our “Information for Authors”. Specific guidelines related to Clinical Trials are also provided.
Conflict of Interest Disclosure – The disclosure statement must be formatted as “I/We have read and understood Current Oncology’s policy on conflicts of interest disclosure and declare the following interests: [list them or state that you have none].”

Current Oncology is Seeking Reviewers

Current Oncology is always seeking qualified and dedicated reviewers to assist with the manuscript review process. As a reviewer you will be asked to read and critique articles. Reviewers play an integral part in ensuring that the high standards of Current Oncology are met and that the articles published are of interest to the oncology community. Please take a moment to register on our website.

***
ReadersChoice-COn

Have you had the chance to view these Current Oncology “Most-Read” articles?

Most Read Articles in PubMed Central (July 2014)

Legalizing euthanasia or assisted suicide: the illusion of safeguards and controls
Pereira J.
Curr Oncol. 2011 Apr;18(2):e38-45

Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature
Salvo N, Barnes E, van Draanen J, Stacey E, Mitera G, Breen D, Giotis A, Czarnota G, Pang J, De Angelis C.
Curr Oncol. 2010 Aug;17(4):94-112

Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1
Sagar SM, Yance D, Wong RK
Curr Oncol. 2006 Feb;13(1):14-26


Most Read Recently* Published Articles at www.current-oncology.com

Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge
Xu T, Tang J, Gu M, Liu L, Wei W, Yang H
Curr Oncol. 2013 Oct;20(5):e406-19. doi: 10.3747/co.20.1456

Patients' perceptions of gene expression profiling in breast cancer treatment decisions
Bombard Y, Rozmovits L, Trudeau ME, Leighl NB, Deal K, Marshall DA
Curr Oncol. 2014 Apr;21(2):e203-11. doi: 10.3747/co.21.1524

A Canadian perspective on the safe administration of bendamustine and the prevention and management of adverse events
Koolwine J, Crosbie T, Gazzé G, Turner R, Wiernikowski J, Assaily W
Curr Oncol. 2014 Feb;21(1):35-42. doi: 10.3747/co.21.1855

*Published within past 12 months

***
CO-NEWS-MEETINGALERT

International Conference on Cancer Nursing (ICCN) 2015 – Vancouver, Canada
Cancer Nursing Research: Global Strategies and Implications for Evidence Based Practice

Date: July 8 – 11, 2015
Venue: Westin Bayshore
Location: Vancouver, Canada

The International Conference on Cancer Nursing (ICCN) 2015 offers a unique opportunity to meet with international cancer nursing leaders from all over the world, in one place, at one time. ICCN is the longest running international conference for our profession.

Register online or submit an abstract or session proposal to join us at this exciting event! Visit the ICCN 2015 webpage for more meeting information.

***
300 x 80px-01

Being well informed is essential when making conscious choices about cancer. CKN is committed to distilling first-rate medical research into practical narratives designed to improve the quality of life of those living with cancer and their medical teams. The CKN approach to living with cancer is unique: while supporting studies that speak to the power that personal connections hold in the healing process, we deliver relevant narratives addressing topics that are less acknowledged in mainstream cancer culture – written by both professionals and experienced lay people. Our mission is to inform our readers in practical ways so that they are able to make solid, conscious choices in their day to day living and improve their quality of life in the process. CKN is published by Multimed Inc.

***
QuickLinks-CON
***

Contact Us

Email-CON
 
Address-CON
 
Phone-CON
 
Web-CON
twitter
1px